Sherry Soefje
Psychiatry · Oceanside, CANPI 1639260201
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,015 of the $5,725 with a category attached, or 70.1%. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 37.6% of the total. 2025 is the largest year on record at $2,336, 9.8 times the $238 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $98.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Boehringer Ingelheim$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$331
- Galderma Laboratories, L.p.$143
- Janssen Research & Development, LLC$106
- plus $131 from 2 others
Across 1,645 payments — averaging $7244.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2.9M
- Teva Pharmaceuticals USA, Inc.$1.8M
- Sage Therapeutics, LLC$1.1M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$961K
- Bioxcel Therapeutics, Inc.$711K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$654K
- plus $3.8M from 23 others
What the payments were for
- Travel & lodging$4,01570%
- Food & beverage$1,67829%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 15 | $2,150 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $1,547 |
| Boehringer Ingelheim | 10 | $1,317 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $331 |
| Galderma Laboratories, L.p. | 1 | $143 |
| Janssen Research & Development, LLC | 1 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $99 |
| AbbVie | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,725 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $38,503 |
| Trazodone Hcl | 19 | $54 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oceanside
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.